The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
- PMID: 2581135
- DOI: 10.1056/NEJM198505303122203
The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Abstract
Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease. To compare the biochemical abnormalities produced by this compound in human beings with those occurring in Parkinson's disease, we examined biogenic amine metabolites in cerebrospinal fluid and urine from six patients with MPTP-induced parkinsonism and eight patients with Parkinson's disease. In both forms of parkinsonism, the cerebrospinal fluid levels of homovanillic acid, the major metabolite of dopamine, were reduced, whereas the levels of the serotonin metabolite 5-hydroxyindoleacetic acid were normal. The cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylethylene glycol (MHPG), the major metabolite of norepinephrine in the brain, after adjustment for plasma MHPG, were elevated (greater than 6.0 ng per milliliter) in MPTP-induced parkinsonism, whereas MHPG levels were reduced (less than 6.0) in Parkinson's disease. Neurons containing norepinephrine in the brain are involved in the degenerative process of Parkinson's disease, whereas they are spared in MPTP-induced parkinsonism. The selective destruction by MPTP of nigrostriatal dopamine neurons that is responsible for the movement disorder also appears to result in an increase in central noradrenergic activity, which is not possible in Parkinson's disease. Thus, differences in central noradrenergic activity, reflected in cerebrospinal fluid levels of MHPG, distinguish these two forms of parkinsonism.
Similar articles
-
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.J Neural Transm Suppl. 1986;20:11-39. J Neural Transm Suppl. 1986. PMID: 3091760 Review.
-
[A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].No To Shinkei. 1987 Jul;39(7):663-72. No To Shinkei. 1987. PMID: 3314916 Review. Japanese.
-
The clinical syndrome of striatal dopamine deficiency: parkinsonism induced by MPTP.N Engl J Med. 1985 Oct 31;313(18):1159-60. doi: 10.1056/NEJM198510313131813. N Engl J Med. 1985. PMID: 3876508 No abstract available.
-
[Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].Fortschr Neurol Psychiatr. 1989 Apr;57(4):142-8. doi: 10.1055/s-2007-1000755. Fortschr Neurol Psychiatr. 1989. PMID: 2656447 Review. German.
-
On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat.J Pharmacol Exp Ther. 1987 May;241(2):669-76. J Pharmacol Exp Ther. 1987. PMID: 2437293
Cited by
-
The Importance of Stem Cells Isolated from Human Dental Pulp and Exfoliated Deciduous Teeth as Therapeutic Approach in Nervous System Pathologies.Cells. 2023 Jun 22;12(13):1686. doi: 10.3390/cells12131686. Cells. 2023. PMID: 37443720 Free PMC article. Review.
-
Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions.Signal Transduct Target Ther. 2023 Feb 21;8(1):73. doi: 10.1038/s41392-023-01353-3. Signal Transduct Target Ther. 2023. PMID: 36810524 Free PMC article. Review.
-
Therapeutic Strategies and Metal-Induced Oxidative Stress: Application of Synchrotron Radiation Microbeam to Amyotrophic Lateral Sclerosis in the Kii Peninsula of Japan.Front Neurol. 2022 Jun 28;13:884439. doi: 10.3389/fneur.2022.884439. eCollection 2022. Front Neurol. 2022. PMID: 35837234 Free PMC article. Review.
-
The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain.Front Aging Neurosci. 2021 Jul 13;13:654931. doi: 10.3389/fnagi.2021.654931. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34326765 Free PMC article. Review.
-
Clinical Insights into Mitochondrial Neurodevelopmental and Neurodegenerative Disorders: Their Biosignatures from Mass Spectrometry-Based Metabolomics.Metabolites. 2021 Apr 10;11(4):233. doi: 10.3390/metabo11040233. Metabolites. 2021. PMID: 33920115 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources